In this study, we demonstrated that MIR29A, LOX, LOXL2, and VEGFA represent a panel of differential biomarkers and independent prognostic factors for HCC patients and that MIR29A acts as a common suppressor on these genes to impede the metastatic behaviors of HCC. This evidence concerns the gene LOXL2 and hepatocellular carcinoma.